{"entity":{"id":"nct06242418","kind":"trial","name":"CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)","aka":["REVISE"],"tldr":"A phase 2 trial of FOLFOXIRI and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by West China Hospital, now recruiting.","summary":"CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) is a phase 2, randomised interventional study registered as NCT06242418 by West China Hospital, with a registry enrolment figure of 60 participants, started 2024-03-25 and due to reach its primary completion in 2025-12-31. Interventions recorded: FOLFOXIRI; XELOX. Conditions listed: Colon Cancer. Primary outcome: change in value of ctDNA concentration. Colorectal eligibility wording from the registry: \"Tumor located in the colon (the distance from the lower margin of the tumor to the anus is greater than 12 cm)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06242418","url":"https://clinicaltrials.gov/study/NCT06242418"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","mrd-testing","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["folfoxiri","capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06242418","phase":"2","setting":"Value of CtDNA in Surveillance of Adjuvant Chemosensitivity and Regimen Adjustment in Stage III Colon Cancer: a Phase II Randomized Controlled Trial (REVISE Trial)","sponsor":"West China Hospital","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06242418/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}